Company intelligence / Profile preview

Checkmate Pharmaceuticals

Cambridge, Massachusetts, United Statescheckmatepharma.com ↗

Ownership: Private
Employees: ~31
Development stage: Other

Overview

Checkmate Pharmaceuticals developed vidutolimod/CMP‑001, a next-generation TLR9 agonist delivered as a virus-like particle. In clinical trials, vidutolimod showed promising activity in PD‑1 blockade-refractory melanoma with RECIST response rates of ~20% as monotherapy and ~23.5% when combined with pembrolizumab. The combination also demonstrated durable responses with median duration exceeding two years in some patients. The company expanded development into additional solid tumor indications including HNSCC, CSCC, and MCC before being acquired by Regeneron.[8]

Therapeutic areas: Oncology
Modalities: Large molecules (biologics)Virus-like particles (VLPs)CpG-A oligonucleotides (TLR9 agonists)
Industry: Biotech

Partnerships

Regeneron Pharmaceuticals—clinical supply agreement to evaluate combinations with Libtayo®(cemiplimab); later acquired the company outright.Sanofi—via Libtayo® co-development partnership through Regeneron/Sanofi collaboration.Pembrolizumab/nivolumab partnerships are investigator/supply-based rather than formal corporate alliances.

Beyond the preview

Go deeper on Checkmate Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Checkmate Pharmaceuticals.